Clene (CLNN) News Today $6.38 +0.05 (+0.71%) As of 12:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLNN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Benchmark Lowers Clene (NASDAQ:CLNN) Price Target to $31.00September 12, 2025 | marketbeat.comClene (NASDAQ:CLNN) Given New $31.00 Price Target at BenchmarkSeptember 11, 2025 | americanbankingnews.comClene price target lowered to $31 from $33 at BenchmarkSeptember 11, 2025 | msn.comClene files to sell 491,496 shares of common stock for holdersSeptember 6, 2025 | msn.comClene Expands Equity Distribution to Raise CapitalSeptember 5, 2025 | tipranks.comClene presents preclinical data supporting CNM-Au8 for Parkinson’s diseaseSeptember 5, 2025 | msn.comClene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s DiseaseSeptember 5, 2025 | finance.yahoo.comClene Inc. Presents Promising Preclinical Data for CNM-Au8 in Parkinson’s Disease Model at H2 Therapeutics Stewardship MeetingSeptember 4, 2025 | quiverquant.comQClene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's DiseaseSeptember 4, 2025 | globenewswire.comClene (NASDAQ: CLNN) Builds Late-Stage Momentum in Neuro PipelineSeptember 3, 2025 | theglobeandmail.comClene to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comClene Inc. (NASDAQ:CLNN) Receives Consensus Recommendation of "Buy" from AnalystsAugust 28, 2025 | marketbeat.comGeneral Resonance Llc Sells 3,401 Shares of Clene (NASDAQ:CLNN) StockAugust 22, 2025 | insidertrades.comClene price target lowered to $48 from $83 at CanaccordAugust 18, 2025 | msn.comClene Inc. Reports Q2 2025 Financial ResultsAugust 14, 2025 | tipranks.comClene Amends Notes and Secures New FinancingAugust 14, 2025 | msn.comClene reports Q2 EPS (78c) vs ($1.06) last yearAugust 14, 2025 | msn.comClene Reports Second Quarter 2025 Financial Results and Recent Operating HighlightsAugust 14, 2025 | globenewswire.comClene (NASDAQ: CLNN) to Present Corporate Update at Emerging Growth Conference on Aug. 20August 14, 2025 | theglobeandmail.comClene to Present at the Emerging Growth ConferenceAugust 13, 2025 | globenewswire.comClene to Present at the Canaccord 45th Annual Growth ConferenceAugust 5, 2025 | globenewswire.comClene (NASDAQ: CLNN) Builds Momentum to Bring New Hope to Neuro PatientsJuly 28, 2025 | theglobeandmail.comClene files prospectus supplement for $2 million stock offering under existing agreement - Investing.com UKJuly 5, 2025 | uk.investing.comClene Inc. (CLNN) Latest Stock News & Headlines - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comClene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA MeetingsJune 30, 2025 | globenewswire.comClene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on ...June 9, 2025 | gurufocus.comClene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on ...June 9, 2025 | gurufocus.comClene Faces Nasdaq Delisting Risk Amid Regulatory PursuitsMay 7, 2025 | tipranks.comClene Inc. Announces Participation in the D. Boral Capital Inaugural Global ConferenceMay 7, 2025 | finance.yahoo.comClene Reports First Quarter 2025 Financial Results and Recent Operating HighlightsMay 7, 2025 | globenewswire.comClene initiated with a Buy at JonesResearchApril 24, 2025 | markets.businessinsider.comJones Trading Initiates Coverage of Clene (CLNN) with Buy RecommendationApril 23, 2025 | msn.comClene to Present at the Emerging Growth ConferenceApril 14, 2025 | globenewswire.comClene announces evidence of remyelination, neuronal repair with CNM-Au8April 8, 2025 | markets.businessinsider.comClene to Present at the Jones Healthcare and Technology Innovation ConferenceApril 1, 2025 | globenewswire.comClene files $160M mixed securities shelfMarch 25, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Clene (CLNN)March 25, 2025 | markets.businessinsider.comClene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025March 25, 2025 | finance.yahoo.comEQS-News: Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025March 25, 2025 | markets.businessinsider.comClene Inc. Reports 2024 Financial Results and Strategic PlansMarch 24, 2025 | tipranks.comClene sees cash runway into 2Q25March 24, 2025 | markets.businessinsider.comClene Inc.: Clene Reports Full Year 2024 Financial Results and Recent Operating HighlightsMarch 24, 2025 | finanznachrichten.deClene Inc. Plans NDA Submission for CNM-Au8® in ALS and Initiates Phase 3 RESTORE-ALS Trial in 2025March 24, 2025 | quiverquant.comQClene Reports Full Year 2024 Financial Results and Recent Operating HighlightsMarch 24, 2025 | globenewswire.comBullish Clene Insiders Loaded Up On US$583.4k Of StockMarch 20, 2025 | uk.finance.yahoo.comClene Inc.: Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 TreatmentMarch 12, 2025 | finanznachrichten.deClene announces evidence from post-hoc analysis of HEALY ALS platform trialMarch 12, 2025 | markets.businessinsider.comClene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® TreatmentMarch 12, 2025 | globenewswire.comClene (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor SummitMarch 7, 2025 | theglobeandmail.comClene Inc. to Participate in 37th Annual Roth Conference with Virtual Fireside Chat and Investor MeetingsMarch 6, 2025 | quiverquant.comQ Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLNN Media Mentions By Week CLNN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLNN News Sentiment▼0.200.92▲Average Medical News Sentiment CLNN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLNN Articles This Week▼52▲CLNN Articles Average Week Get the Latest News and Ratings for CLNN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Clene and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ANNX News Today VYGR News Today LYEL News Today TKNO News Today TNXP News Today SGMT News Today ACIU News Today ACRS News Today HUMA News Today AVTE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLNN) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
